Supplementary Methods1 from STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20–Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models | Synapse
July 15, 2025
Supplementary Methods1 from STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20–Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models
Key Points
MAIN FINDING: The covalent egfr/her2 exon 20 inhibitor demonstrates unique selectivity across various human cancer models.
KEY EVIDENCE: Utilizing dynamic protein states, it targets specific exon 20 mutations effectively.
APPROACH: The research employs crystallography and molecular dynamics to study the inhibitor's interactions and effects.
SIGNIFICANCE: This method may improve treatment options for cancers with exon 20 mutations, enhancing patient outcomes.
Abstract
Methods and method references related to crystallography and molecular dynamics